淋巴结清扫在肾细胞癌治疗中的作用:系统综述与Meta分析
该系统综述与Meta分析评估了腹膜后淋巴结清扫(LND)在非转移性(M0)和转移性(M1)肾细胞癌(RCC)中的作用。共纳入51项研究,结果显示LND与M0、M1或合并人群的全因死亡率均无显著关联,现有证据不支持LND具有治疗获益。
要点
- LND与M0和M1肾细胞癌的全因死亡率均无显著关联。
- 高危M0患者行LND未显示肿瘤学结局改善,需进一步研究。
- 淋巴结受累是M0和M1肾细胞癌的独立不良预后因素。
核心结论
- 现有文献不支持淋巴结清扫在M0或M1肾细胞癌中具有治疗获益。
- 淋巴结清扫可提供独立预后信息,但并非治疗手段。
研究设计与样本
- 系统综述与随机效应Meta分析,检索Medline、EMBASE、Web of Science和Scopus至2017年8月29日。
- 共纳入51项独特研究进行定性系统综述,偏倚风险低者占41/51(80%)。
主要发现
- LND与全因死亡率在M0(HR 1.02,95%CI 0.92-1.12;I²=0%;4项研究)、M1(HR 1.04,95%CI 0.83-1.29;I²=0%;2项研究)及合并人群(HR 1.00,95%CI 0.92-1.09;I²=0%;7项研究)均无显著关联。
- 按M分期亚组分析无统计学显著差异(P=0.50)。
- 三项研究探讨高危淋巴结转移M0亚组,LND未与肿瘤学结局改善相关。
- 淋巴结受累在M0和M1情况下均与不良预后独立相关。
- pN1M0患者中一小部分术后可获得长期肿瘤学控制,10年癌症特异性生存率为21-31%。
关键数值与推荐
- GRADE证据质量:所评估结局为中等或低质量。
临床怎么用
- 对于M0或M1肾细胞癌,不推荐以治疗为目的行常规淋巴结清扫。
- 淋巴结清扫可用于获取预后信息,但需权衡手术风险。
- 高危M0患者可考虑个体化决策,并鼓励参与进一步研究。
局限性
- 纳入研究以回顾性为主,存在混杂可能。
- 关于淋巴结清扫范围与生存关联的研究结果不一致。
- GRADE证据质量评为中等或低,结论需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Our objective was to evaluate the role of retroperitoneal lymph node dissection (LND) in non-metastatic (M0) and metastatic (M1) renal cell carcinoma (RCC). We searched Medline, EMBASE, Web of Science and Scopus from database inception to 29 August 2017 for studies of patients who underwent partial or radical nephrectomy for M0 or M1 RCC. Two investigators independently selected studies for inclusion. Risk of bias was assessed using the Newcastle-Ottawa scale, Cochrane Collaboration tool and National Heart, Lung and Blood Institute Quality Assessment Tool. Random effects meta-analysis was performed for all-cause-mortality. The GRADE approach was used to characterize quality of evidence. A total of 51 unique studies were included in the qualitative systematic review. Risk of bias was low in 41/51 (80%) studies. LND was not associated with all-cause mortality in either M0 (hazard ratio [HR] 1.02, 95% confidence interval [CI] 0.92-1.12; I2 = 0%; four studies), M1 (HR 1.04, 95% CI 0.83-1.29; I2 = 0%; two studies), or pooled M0 and M1 settings (HR 1.00, 95% CI 0.92-1.09; I2 = 0%; seven studies), with no statistically significant differences according to M stage subgroups (P = 0.50). In the three studies that examined M0 subgroups with a high risk of nodal metastasis, LND was not associated with improved oncological outcomes. Studies on the association of extent of LND with survival reported inconsistent results. Meanwhile, a small proportion of patients with pN1M0 disease demonstrate durable long-term oncological control after surgery, with 10-year cancer-specific survival of 21-31%. Nodal involvement is independently associated with adverse prognosis in both M0 and M1 settings. GRADE quality of evidence was moderate or low for the outcomes examined. Although LND yields independent prognostic information, the existing literature does not support a therapeutic benefit to LND in either M0 or M1 RCC. High-risk M0 patient groups warrant further study, as a subset of patients with isolated nodal metastases experience long-term survival after surgical resection.
引用
- Bhindi B, Wallis CJD, Boorjian SA, et al. The role of lymph node dissection in the management of renal cell carcinoma: a systematic review and meta-analysis. BJU Int. 2018. PMID: 29319926. doi:10.1111/bju.14127
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。